Suppr超能文献

相似文献

1
Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease.
Kidney Int. 2011 Mar;79(6):663-670. doi: 10.1038/ki.2010.484. Epub 2010 Dec 15.
2
Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss.
J Am Soc Nephrol. 2020 Apr;31(4):865-875. doi: 10.1681/ASN.2019050497. Epub 2020 Mar 3.
3
Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease.
PLoS One. 2014 Nov 11;9(11):e112188. doi: 10.1371/journal.pone.0112188. eCollection 2014.
4
One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease.
PLoS One. 2016 Apr 15;11(4):e0152812. doi: 10.1371/journal.pone.0152812. eCollection 2016.
8
Podocyturia is significantly elevated in untreated vs treated Fabry adult patients.
J Nephrol. 2016 Dec;29(6):791-797. doi: 10.1007/s40620-016-0271-z. Epub 2016 Feb 3.
10
Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients.
Nephrol Dial Transplant. 2017 May 1;32(5):807-813. doi: 10.1093/ndt/gfw094.

引用本文的文献

2
Urinary Myeloid Bodies as a Biomarker for Early Diagnosis and Monitoring of Enzyme Replacement Therapy in Fabry Disease.
Kidney Dis (Basel). 2025 Apr 14;11(1):332-341. doi: 10.1159/000545604. eCollection 2025 Jan-Dec.
3
The Role of Kidney Biopsy in Fabry Disease.
Biomedicines. 2025 Mar 21;13(4):767. doi: 10.3390/biomedicines13040767.
4
Fabry Disease: Insights into Pathophysiology and Novel Therapeutic Strategies.
Biomedicines. 2025 Mar 4;13(3):624. doi: 10.3390/biomedicines13030624.
5
Anderson-Fabry Disease: Focus on Ophthalmological Implications.
Life (Basel). 2024 Nov 22;14(12):1531. doi: 10.3390/life14121531.
6
Targeted nanoliposomes to improve enzyme replacement therapy of Fabry disease.
Sci Adv. 2024 Dec 13;10(50):eadq4738. doi: 10.1126/sciadv.adq4738.
7
No differences in native T1 of the renal cortex between Fabry disease patients and healthy subjects in cardiac-dedicated native T1 maps.
J Cardiovasc Magn Reson. 2024;26(2):101104. doi: 10.1016/j.jocmr.2024.101104. Epub 2024 Sep 25.
9
The role of podocyte injury in the pathogenesis of Fabry disease nephropathy.
J Bras Nefrol. 2024 Jul-Sep;46(3):e20240035. doi: 10.1590/2175-8239-JBN-2024-0035en.

本文引用的文献

1
Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry.
Clin J Am Soc Nephrol. 2010 Dec;5(12):2220-8. doi: 10.2215/CJN.04340510. Epub 2010 Sep 2.
2
Scoring system for renal pathology in Fabry disease: report of the International Study Group of Fabry Nephropathy (ISGFN).
Nephrol Dial Transplant. 2010 Jul;25(7):2168-77. doi: 10.1093/ndt/gfp528. Epub 2009 Oct 15.
3
Decreased nitric oxide bioavailability in a mouse model of Fabry disease.
J Am Soc Nephrol. 2009 Sep;20(9):1975-85. doi: 10.1681/ASN.2008111190. Epub 2009 Jul 23.
4
Agalsidase alfa and kidney dysfunction in Fabry disease.
J Am Soc Nephrol. 2009 May;20(5):1132-9. doi: 10.1681/ASN.2008080870. Epub 2009 Apr 8.
6
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy.
Nephrol Dial Transplant. 2009 Jul;24(7):2102-11. doi: 10.1093/ndt/gfp031. Epub 2009 Feb 13.
7
Angiokeratoma corporis diffusum (universale) Fabry, as a sign of an unknown internal disease; two autopsy reports.
Acta Med Scand. 1947 Jun 30;128(3):234-55. doi: 10.1111/j.0954-6820.1947.tb06596.x.
8
Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria.
Am J Kidney Dis. 2008 May;51(5):767-76. doi: 10.1053/j.ajkd.2007.12.032. Epub 2008 Mar 20.
10
Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.
Mol Genet Metab. 2008 Feb;93(2):112-28. doi: 10.1016/j.ymgme.2007.09.013. Epub 2007 Nov 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验